Maggot therapy using medical aseptic flies larvae for refractory chronic skin ulcer

Maggot therapy using medical aseptic flies larvae for refractory chronic skin ulcer - Maggot therapy for chronic skin ulcer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018861

Enrollment

Registered

2015-08-31

Start date

2015-10-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Diabetic ulcer or Diabetic gangrene,2.Decubitus, 3. Leg ulcer due to ischemia, stasis, systemic sclerosis etc.

Interventions

medical aseptic flies larvae

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Untraceable chronic skin ulcer due to diabetic ulcer or diabetic gangrene, Decubitus, leg ulcer due to ischemia, stasis, and systemic sclerosis etc.

Exclusion criteria

Exclusion criteria: 1. Patient who is not accepted the maggot therapy, 2. Severe blood flow obstruction, 3. Rapid exacerbated infection, 4. Poorly controlled collagen vascular disease, 5. Visible large vessels can be detected on the ulcer or connected to inside of the body, 6. Uncontrolled hemorrhagic disease, 7. Sensitivity for medical maggot. 8. In appropriate case judged by a doctor.

Design outcomes

Primary

Measure	Time frame
1.Ulcer size and depth,2.Pain assessment using visual analog scale, 3.Blood test,4.Bacterial culture,5.The therapy will 6.The therapy will be finished when the ulcer seems to be closed by skin grafts. Those assessment will be performed before treatment and 2,3,4,5 weeks and 6 months after treatment.	—

Countries

Japan

Contacts

Public ContactMari Kishibe

Asahikawa Medical University Dermatology

mkishibe@asahikawa-med.ac.jp0166-68-2523

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026